Vedanta strikes deal with Janssen for IBD therapy
This article was originally published in Scrip
Executive Summary
Janssen, a subsidiary of Johnson & Johnson, has entered a license agreement with Vedanta Biosciences to develop the latter firm's lead microbiome pharmaceutical candidate, VE202, for inflammatory bowel disease (IBD).
You may also be interested in...
Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Deal Watch: Millendo Completes Merger With OvaScience, With $85m In Bank For Two Mid-Stage Programs
OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.
Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.